Form 8-K - Current report:
SEC Accession No. 0001641172-25-024520
Filing Date
2025-08-18
Accepted
2025-08-18 06:30:39
Documents
13
Period of Report
2025-08-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 41106
2 EX-10.1 ex10-1.htm EX-10.1 62478
  Complete submission text file 0001641172-25-024520.txt   284744

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE mtnb-20250815.xsd EX-101.SCH 3038
4 XBRL LABEL FILE mtnb-20250815_lab.xml EX-101.LAB 34915
5 XBRL PRESENTATION FILE mtnb-20250815_pre.xml EX-101.PRE 22804
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3884
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38022 | Film No.: 251226231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)